Cardiorenal outcomes in eligible patients referred for bariatric surgery

Objective Bariatric surgery is associated with reduced atherosclerotic cardiovascular disease (CVD) and heart failure hospitalization in people with type 2 diabetes (T2D) and those with prior CVD. Most patients undergoing bariatric surgery do not have T2D or CVD. Many otherwise eligible patients do...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Obesity (Silver Spring, Md.) Md.), 2021-12, Vol.29 (12), p.2035-2043
Hauptverfasser: Dash, Satya, Everett, Karl, Jackson, Timothy, Okrainec, Allan, Urbach, David R., Sockalingam, Sanjeev, Shah, Baiju R., Farkouh, Michael E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Bariatric surgery is associated with reduced atherosclerotic cardiovascular disease (CVD) and heart failure hospitalization in people with type 2 diabetes (T2D) and those with prior CVD. Most patients undergoing bariatric surgery do not have T2D or CVD. Many otherwise eligible patients do not have surgery because of self‐exclusion. Clinical outcomes in these groups are less established. Methods This study retrospectively assessed cardiorenal outcomes in 8,568 patients after acceptance of referral for surgery. Results A total of 63.8% patients did not undergo surgery. After multivariate adjustment for sex, age, BMI, income quintile, distance from hospital, hypertension, T2D, and CVD, hazard ratios (HR) for the primary (incident myocardial infarction, stroke, heart failure hospitalization, and death; HR = 0.52, 95% CI: 0.4‐0.66) and secondary CVD outcomes (primary outcomes and coronary/carotid revascularization; HR = 0.53, 95% CI: 0.42‐0.67) were lower in the surgery cohort. This reduction was seen in those with (primary: HR = 0.45, 95% CI: 0.32‐0.63, secondary: HR = 0.47, 95% CI: 0.34‐0.65) and without T2D (primary: HR = 0.61, 95% CI: 0.42‐0.88, secondary: HR = 0.53, 95% CI: 0.42‐0.67). Reduced kidney disease (HR = 0.46, 95% CI: 0.22‐0.92) but increased liver disease hospitalization (HR = 2.5, 95% CI: 1.45‐4.27) was observed with surgery. Conclusions Non‐progression to surgery associates with increased CVD despite low baseline prevalence of CVD. The cardiorenal benefits of bariatric surgery warrant confirmation in a well‐powered randomized clinical trial.
ISSN:1930-7381
1930-739X
DOI:10.1002/oby.23294